Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Method: Etravirine-resistance mutations were defined as mutations associated in the DUET studies with a decreased virological response to etravirine: V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T,
Method: The mutations V90I, A98G, V106I, E138A, and V179D/T were considered to be less important indicators of etravirine resistance because they are polymorphic (particularly V90I and V106I) and have not been shown to have a phenotypic effect on etravirine susceptibility.
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
Conclusion: Etravirine RAMs include V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L.
Introduction: More recently, further statistical analysis of the pooled 24-week DUET data expanded the original list of 13 etravirine RAMs to 17 with the addition of K101H, E138A, V179T and M23L (Table 5).
HIV mutation literature information.
PMID: 
2009
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT